Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA

Watchlist Manager
Kiniksa Pharmaceuticals Ltd Logo
Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA
Watchlist
Price: 41.59 USD 1.41% Market Closed
Market Cap: 3.2B USD

Wall Street
Price Targets

KNSA Price Targets Summary
Kiniksa Pharmaceuticals Ltd

Wall Street analysts forecast KNSA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for KNSA is 55.08 USD with a low forecast of 45.45 USD and a high forecast of 65.1 USD.

Lowest
Price Target
45.45 USD
9% Upside
Average
Price Target
55.08 USD
32% Upside
Highest
Price Target
65.1 USD
57% Upside
Kiniksa Pharmaceuticals Ltd Competitors:
Price Targets
IPH
Innate Pharma SA
206% Upside
XGN
Exagen Inc
121% Upside
STOK
Stoke Therapeutics Inc
0% Downside
COV
Covalon Technologies Ltd
109% Upside
006280
Green Cross Corp
19% Upside
BNTX
BioNTech SE
47% Upside
7774
Japan Tissue Engineering Co Ltd
154% Upside
ABNX
Abionyx Pharma SA
213% Upside

Revenue
Forecast

Revenue Estimate
Kiniksa Pharmaceuticals Ltd

The compound annual growth rate of Kiniksa Pharmaceuticals Ltd's revenue for the next 3 years is 34%.

N/A
Past Growth
34%
Estimated Growth
Estimates Accuracy
2%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Kiniksa Pharmaceuticals Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
3%
Average Beat

Net Income
Forecast

Net Income Estimate
Kiniksa Pharmaceuticals Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-12%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is KNSA's stock price target?
Price Target
55.08 USD

According to Wall Street analysts, the average 1-year price target for KNSA is 55.08 USD with a low forecast of 45.45 USD and a high forecast of 65.1 USD.

What is Kiniksa Pharmaceuticals Ltd's Revenue forecast?
Projected CAGR
34%

The compound annual growth rate of Kiniksa Pharmaceuticals Ltd's revenue for the next 3 years is 34%.

Back to Top